According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Wound treatment
Surgical wound complications
- Proteins in wound healing
Do special amino acids lead to success?
- Proteins in wound healing
Do special amino acids lead to success?
- Psychedelic-assisted therapy
Current status of PAT
- Hepatitis B prophylaxis
Vaccination protection for healthcare staff with patient contact – an update
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Chronic urticaria: new treatment alternatives in sight
If antihistamines are not sufficient and IgE levels are low
- Adrenogenital syndrome